Esiti a lungo termine delle infusioni di lidocaina per la prova del dolore post-operatorio (LOLIPOP). (LOLIPOP)
The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The Trial's purpose is to evaluate the effectiveness of lidocaine infusions commenced during surgery and extending up to 24 hours postoperatively, on the incidence of moderate or severe chronic post-surgical pain (CPSP) detected one year following surgery in female patients undergoing elective breast cancer surgery. The trial has 90% power to detect a clinically meaningful (25%) reduction in the incidence of the primary outcome. Secondary outcomes include safety events, analgesic efficacy (pain scores and opioid consumption), neuropathic characteristics of CPSP, and psychological and quality of life outcomes.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Gillian Ormond
- Numero di telefono: +610399030387
- Email: gillian.ormond@monash.edu
Backup dei contatti dello studio
- Nome: Natalie Hird
- Numero di telefono: +61 (0) 459 407 231
- Email: natalie.hird@health.wa.gov.au
Luoghi di studio
-
-
New South Wales
-
Kingswood, New South Wales, Australia, 2747
- Reclutamento
- Nepean Hospital
-
Mount Druitt, New South Wales, Australia, 2770
- Reclutamento
- Blacktown Mount Druitt Hospital
-
Sydney, New South Wales, Australia, 2217
- Reclutamento
- St George Hospital
-
Sydney, New South Wales, Australia, 2145
- Completato
- Westmead Hospital
-
Sydney, New South Wales, Australia, 2035
- Reclutamento
- Royal North Shore Hospital
-
-
Queensland
-
Brisbane, Queensland, Australia, 4029
- Completato
- Royal Brisbane and Women's Hospital
-
Coopers Plains, Queensland, Australia, 4108
- Attivo, non reclutante
- Queen Elizabeth II Jubilee Hospital
-
Mackay, Queensland, Australia, 4740
- Attivo, non reclutante
- Mackay Base Hospital
-
Rockhampton, Queensland, Australia, 4700
- Completato
- Rockhampton Hospital
-
Southport, Queensland, Australia, 4215
- Completato
- Gold Coast Hospital and Health Service- Gold Coast University Hospital
-
Woolloongabba, Queensland, Australia, 4102
- Reclutamento
- Princess Alexandra Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Reclutamento
- Flinders Medical Centre
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Reclutamento
- Royal Hobart Hospital
-
-
Victoria
-
Ballarat, Victoria, Australia, 3350
- Completato
- Anaesthetic Group Ballarat
-
Ballarat, Victoria, Australia, 3350
- Attivo, non reclutante
- Ballarat Health Services (Grampians Health)
-
Geelong, Victoria, Australia, 3220
- Reclutamento
- Barwon Health - University Hospital Geelong
-
Melbourne, Victoria, Australia, 3065
- Reclutamento
- St Vincent's Hospital Melbourne
-
Melbourne, Victoria, Australia, 3004
- Reclutamento
- The Alfred
-
Melbourne, Victoria, Australia, 3050
- Attivo, non reclutante
- Royal Melbourne Hospital
-
Melbourne, Victoria, Australia, 3165
- Completato
- Monash Health - Moorabbin Hospital
-
Melbourne, Victoria, Australia, 3076
- Ritirato
- Northern Hospital
-
Ringwood East, Victoria, Australia, 3135
- Reclutamento
- Maroondah Hospital - Eastern Health
-
Shepparton, Victoria, Australia, 3630
- Completato
- Goulburn Valley Health
-
Traralgon, Victoria, Australia, 3844
- Ritirato
- Latrobe Regional Hospital
-
-
Western Australia
-
Bentley, Western Australia, Australia, 6102
- Reclutamento
- Bentley Health Service
-
Perth, Western Australia, Australia, 6000
- Reclutamento
- Royal Perth Hospital
-
Perth, Western Australia, Australia, 6008
- Reclutamento
- St John of God Subiaco
-
-
-
-
-
Chai Wan, Hong Kong
- Reclutamento
- Pamela Youde Nethersole Eastern Hospital
-
Wan Chai, Hong Kong
- Reclutamento
- Ruttonjee Hospital
-
-
Sha Tin
-
Shatin, Sha Tin, Hong Kong
- Reclutamento
- North District Hospital
-
-
-
-
Auckland
-
Auckland, Auckland, Nuova Zelanda, 1023
- Reclutamento
- Auckland City Hospital
-
-
Middlemore
-
Auckland, Middlemore, Nuova Zelanda, 2025
- Reclutamento
- Middlemore Hospital
-
-
Waikato Region
-
Hamilton, Waikato Region, Nuova Zelanda, 3204
- Reclutamento
- Waikato Hospital
-
-
-
-
-
Belfast, Regno Unito, BT9 7AB
- Reclutamento
- Belfast City Hospital
-
Bristol, Regno Unito, BS10 5NB
- Reclutamento
- Southmead Hospital, North Bristol Trust
-
Darlington, Regno Unito, DL3 6HX
- Terminato
- Darlington Memorial Hospital
-
Dudley, Regno Unito, DY1 2HQ
- Reclutamento
- Russells Hall Hospital
-
Liverpool, Regno Unito
- Reclutamento
- Royal Liverpool and Broadgreen Hospitals
-
London, Regno Unito, N19 5NF
- Reclutamento
- Whittington Hospital
-
London, Regno Unito
- Reclutamento
- Royal Marsden Hospital - London and Sutton
-
Newcastle upon Tyne, Regno Unito
- Reclutamento
- Newcastle upon Tyne Hospitals
-
Norwich, Regno Unito, NR4 7UY
- Reclutamento
- Norfolk and Norwich University Hospital
-
Rotherham, Regno Unito, S60 2UD
- Reclutamento
- Rotherham NHS Foundation Trust
-
Sheffield, Regno Unito, S10 2JF
- Reclutamento
- Royal Hallamshire Hospital
-
Southampton, Regno Unito
- Reclutamento
- University Hospital Southampton
-
St Helens, Regno Unito, WA9 3DA
- Reclutamento
- St Helen's Hospital
-
Torquay, Regno Unito, TQ2 7AA
- Attivo, non reclutante
- Torbay Hospital
-
Winchester, Regno Unito, SO22 5DG
- Reclutamento
- Royal Hampshire County Hospital
-
-
Scotland
-
Wishaw, Scotland, Regno Unito
- Reclutamento
- University Hospital Wishaw
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Consenting adult female patients (≥18 years) undergoing mastectomy (unilateral or bilateral) or breast conserving surgery (unilateral or bilateral) for the primary excision of confirmed or suspected primary breast cancer under general anaesthesia (including those with simultaneous insertion of tissue expanders or implants)*. * this specifically excludes patients undergoing surgery for locoregional recurrence
- American Society of Anaesthesiologist (ASA) physical scale 1-3
Exclusion Criteria:
- Mastectomy or breast conserving surgery with add on procedures e.g laparoscopic salpingectomy
- Where surgery is being performed for locoregional recurrence of breast cancer
- Pre-existing pain at site of surgery, axilla, ipsilateral side of chest wall or the ipsilateral upper arm (at diagnosis prior to any tumor locating procedures)
- Re-excision procedures where the margins at the index surgery have been deemed insufficient
- When immediate autologous reconstruction surgery is planned
- Where delayed autologous reconstruction surgery on the operative breast within one year is planned
- Planned use of regional analgesia infusions
- Impaired cognition
- Pregnant or lactating females
- Transgender patients
- Known metastatic disease
- History of anaphylaxis, sensitivity or known contraindication to lidocaine (or other amide local anaesthetic agents e.g. other amide local anaesthetic agents: ropivacaine, bupivacaine, mepivacaine, prilocaine, etidocaine), including patients with porphyria or methaemoglobinaemia
- History of epilepsy
- Baseline heart rate < 50 bpm or systolic blood pressure < 100mmHg.
- Acute coronary event in the last three months
- Cardiac conduction abnormalities, including; Atrial fibrillation, Heart block (all degrees), Bundle Branch Block or Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome. A preoperative Electrocardiogram (ECG) is not mandatory, unless clinically indicated
- Abnormal serum potassium concentration (based upon site laboratory reference ranges)
- Active liver disease e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes)
- Medications within the last 7 days which are known / suspected to slow lidocaine metabolism (amiodarone, beta blockers, cimetidine, fluoroquinolones, fluvoxamine, imidazoles, macrolides, verapamil, HIV drugs)
- Cardiac Failure (any documented heart failure at peroperative assessment or GP records)
- Severe Renal Failure (Creatinine Clearance of less than 30ml/min or dialysis dependent)
- Co-administration of lidocaine within 24 hours prior to surgery for other reasons (e.g. lidocaine patches
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Lidocaine
2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative. |
Lidocaine infusion:
Altri nomi:
|
|
Comparatore placebo: Placebo
0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative. |
Placebo infusion:
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The incidence of moderate or severe CPSP at 1 year after surgery, as reported by the patient at the follow-up review.
Lasso di tempo: 1 year post-surgery
|
Numerical rating scale ≥4 out of 10 for worst pain in the last week - The pain must have been present for at least 3 months prior to the one year assessment (or longer). |
1 year post-surgery
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The incidence of severe CPSP at 1 year after surgery
Lasso di tempo: 1 year post surgery
|
NRS for worst pain the in the last week of ≥7) |
1 year post surgery
|
|
Severity of pain at the site of surgery
Lasso di tempo: 1 year post surgery
|
Assessed using "average" and "worst" NRS pain score in the last week, obtained from the adapted modified Brief Pain Inventory-Short Form (mBPI-SF) |
1 year post surgery
|
|
Incidence of neuropathic symptoms
Lasso di tempo: 1 year post surgery
|
Incidence examined as a binary outcome using the Short Form of Douleur Neuropathique 4 Questions (S-DN4) |
1 year post surgery
|
|
Physical functioning
Lasso di tempo: 1 year post surgery
|
Using interference component of mBPI-SF |
1 year post surgery
|
|
Changes in quality of life metrics EuroQol 5 Dimension 5 Level (EQ-5D-5L) at 1 year after surgery compared to baseline
Lasso di tempo: 1 year post surgery
|
Changes in the quality of life |
1 year post surgery
|
|
Changes in psychological wellbeing Kessler Psychological Distress Scale (K-10) at 1 year after surgery compared to baseline.
Lasso di tempo: 1 year post surgery
|
Changes in psychological wellbeing |
1 year post surgery
|
|
The incidence of mild or greater pain at the site of surgery at 1 year after surgery
Lasso di tempo: 1 year post surgery
|
NRS for worst pain the in the last week of ≥1 |
1 year post surgery
|
|
The incidence of discomfort or altered sensation at the site of surgery (not reported as pain)
Lasso di tempo: 1 year post surgery
|
Patients asked if they have any altered sensation at the site of surgery |
1 year post surgery
|
|
Severity of acute postoperative pain at rest
Lasso di tempo: 24 hours postoperatively
|
Maximum pain score, Numerical rating scale (NRS) 0-10 |
24 hours postoperatively
|
|
Severity of Acute postoperative pain on movement
Lasso di tempo: 24 hours postoperatively
|
Maximum pain score, Numerical rating scale (NRS) 0-10 |
24 hours postoperatively
|
|
Postoperative opioid consumption
Lasso di tempo: on Day 1
|
Morphine Equivalent Opioid Consumption (MEQ) |
on Day 1
|
|
Postoperative opioid consumption
Lasso di tempo: 3 months (last 24-hours)
|
Morphine Equivalent Opioid Consumption (MEQ) |
3 months (last 24-hours)
|
|
Postoperative opioid consumption
Lasso di tempo: 1 year post surgery (last 24 hours)
|
Morphine Equivalent Opioid Consumption (MEQ) |
1 year post surgery (last 24 hours)
|
|
The incidence of mortality at 1 year
Lasso di tempo: 1 year post surgery
|
Mortality at 1 year |
1 year post surgery
|
|
UK NHS costs of care over 1 year following surgery
Lasso di tempo: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
|
Productivity costs over 1 year following surgery
Lasso di tempo: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
|
Quality-adjusted life years (QALYs) over 1 year following surgery
Lasso di tempo: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
|
Cost-effectiveness of perioperative lidocaine infusions compared to usual care, from a primary UK NHS perspective and broader perspective including productivity, at 1 year.
Lasso di tempo: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of treated bradycardia intraoperatively
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of treated hypotension intraoperatively
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of treated bradycardia in Post Anaesthesia Care Unit (PACU)
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of treated hypotension in Post Anaesthesia Care Unit (PACU)
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of intraoperative infusion stopping events
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of Post Anaesthesia Care Unit (PACU) infusion stopping events
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints, (x2 symptoms, x1 sign, x1 complication) |
24 hours postoperatively
|
|
Incidence of postoperative infusion stopping events on the ward
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints, (x2 symptoms, x1 sign, x1 complication) |
24 hours postoperatively
|
|
Incidence of suspected lidocaine toxicity events
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of suspected SEVERE lidocaine toxicity events
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints, (generalised seizure, sudden unexplained LOC, life-threatening arrhythmia, or asystole, cardiac or circulatory arrest) |
24 hours postoperatively
|
|
Incidence of Medical Emergency Team (MET) activation
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of unplanned Intensive Care Unit (ICU), High Dependency Unit (HDU) or Critical Care Unit (CCU) admission
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of study drug unblinding events
Lasso di tempo: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of subcutaneous catheter site events
Lasso di tempo: Day 30
|
Drug related safety Endpoints |
Day 30
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Tomas Corcoran, Royal Perth Hospital
Pubblicazioni e link utili
Pubblicazioni generali
- Toner AJ, Bailey MA, Schug SA, Corcoran TB. A pilot multicentre randomised controlled trial of lidocaine infusion in women undergoing breast cancer surgery. Anaesthesia. 2021 Oct;76(10):1326-1341. doi: 10.1111/anae.15440. Epub 2021 Mar 2.
- Toner AJ, Bailey MA, Schug SA, Phillips M, Ungerer JP, Somogyi AA, Corcoran TB. Serum lidocaine (lignocaine) concentrations during prolonged perioperative infusion in patients undergoing breast cancer surgery: A secondary analysis of a randomised controlled trial. Anaesth Intensive Care. 2023 Nov;51(6):422-431. doi: 10.1177/0310057X231194833. Epub 2023 Oct 6.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Dolore
- Manifestazioni neurologiche
- Complicanze postoperatorie
- Processi patologici
- Neoplasie per sede
- Neoplasie
- Malattie della pelle
- Malattie del seno
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Segni e sintomi
- Dolore, Postoperatorio
- Neoplasie mammarie
- Prodotti chimici organici
- Preparati farmaceutici
- Anilides
- Amides
- Composti di anilina
- Ammine
- Acetanilides
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Lidocaina
- Soluzione salina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HREC/74777/Alfred-2021
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .